L-asparaginase	B:C0003993
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	O
to	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	B:C1704258
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	O
to	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	B:C0455280
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	O
to	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	O
to	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	B:C0184666
to	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	O
to	O
a	O
tertiary	B:C0337954
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
.	O

L-asparaginase	O
-	O
induced	O
abnormality	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
admitted	O
to	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	B:C0017446
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	B:C0220825
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	B:C0205161
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	B:C0455280
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	B:C0332293
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	B:C0003993
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	B:C0003993
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	B:C0392920
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
any	O
abnormal	O
change	O
in	O
plasma	O
glucose	I:C0455280
levels	I:C0455280
in	O
patients	O
treated	O
with	I:C0332293
L	O
-	I:C0003993
asparaginase	I:C0003993
(	O
L	O
-	I:C0003993
asparaginase	I:C0003993
)	O
-	O
based	O
chemotherapy	O
regimen	I:C0392920
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
(	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
)	O
.	O

This	O
retrospective	B:C0035363
,	I:C0035363
hospital	I:C0035363
-	I:C0035363
based	I:C0035363
study	I:C0035363
was	O
conducted	O
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
admitted	O
to	I:C0583283
the	I:C0583283
Clinical	I:C0583283
Haematology	I:C0583283
Department	I:C0583283
of	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

This	O
retrospective	O
,	I:C0035363
hospital	I:C0035363
-	I:C0035363
based	I:C0035363
study	I:C0035363
was	O
conducted	O
in	O
patients	O
of	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
admitted	O
to	I:C0583283
the	I:C0583283
Clinical	I:C0583283
Haematology	I:C0583283
Department	I:C0583283
of	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

This	O
retrospective	O
,	I:C0035363
hospital	I:C0035363
-	I:C0035363
based	I:C0035363
study	I:C0035363
was	O
conducted	O
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
admitted	B:C0583283
to	I:C0583283
the	I:C0583283
Clinical	I:C0583283
Haematology	I:C0583283
Department	I:C0583283
of	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

This	O
retrospective	O
,	I:C0035363
hospital	I:C0035363
-	I:C0035363
based	I:C0035363
study	I:C0035363
was	O
conducted	O
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
admitted	O
to	I:C0583283
the	I:C0583283
Clinical	I:C0583283
Haematology	I:C0583283
Department	I:C0583283
of	O
a	O
tertiary	B:C0337954
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	O
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

This	O
retrospective	O
,	I:C0035363
hospital	I:C0035363
-	I:C0035363
based	I:C0035363
study	I:C0035363
was	O
conducted	O
in	O
patients	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
,	O
admitted	O
to	I:C0583283
the	I:C0583283
Clinical	I:C0583283
Haematology	I:C0583283
Department	I:C0583283
of	O
a	O
tertiary	O
care	I:C0337954
hospital	I:C0337954
of	O
Odisha	B:C0017446
from	O
August	O
2014	O
to	O
July	O
2015	O
.	O

Indoor	B:C0034869
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	O
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	O
glucose	I:C0202042
alteration	O
.	O

Indoor	O
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	B:C0008971
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	O
glucose	I:C0202042
alteration	O
.	O

Indoor	O
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	O
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	B:C0220825
for	O
any	O
alteration	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	O
glucose	I:C0202042
alteration	O
.	O

Indoor	O
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	O
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	B:C0455280
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	O
glucose	I:C0202042
alteration	O
.	O

Indoor	O
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	O
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	B:C0020615
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	O
glucose	I:C0202042
alteration	O
.	O

Indoor	O
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	O
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	B:C0020456
,	O
and	O
persistence	O
of	O
plasma	O
glucose	I:C0202042
alteration	O
.	O

Indoor	O
records	I:C0034869
of	O
146	O
patients	O
on	O
multi-centered	O
protocol	I:C0008971
-	I:C0008971
841	I:C0008971
were	O
evaluated	O
for	O
any	O
alteration	O
in	O
plasma	O
glucose	I:C0455280
level	I:C0455280
,	O
time	O
of	O
onset	O
of	O
hypo	O
/	O
hyperglycemia	O
,	O
and	O
persistence	O
of	O
plasma	B:C0202042
glucose	I:C0202042
alteration	O
.	O

Twenty	O
-	O
one	O
percent	O
of	O
patients	O
showed	O
abnormal	B:C0205161
plasma	O
glucose	I:C0455280
level	I:C0455280
.	O

Twenty	O
-	O
one	O
percent	O
of	O
patients	O
showed	O
abnormal	O
plasma	B:C0455280
glucose	I:C0455280
level	I:C0455280
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	B:C0020615
and	O
were	O
of	O
lower	O
age	O
group	O
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	B:C0020615
and	O
were	O
of	O
lower	O
age	O
group	O
,	O
whereas	O
a	O
majority	O
of	O
higher	O
age	O
group	O
patients	O
developed	O
hyperglycemia	O
.	O

Most	O
of	O
these	O
patients	O
developed	O
hypoglycemia	O
and	O
were	O
of	O
lower	O
age	O
group	O
,	O
whereas	O
a	O
majority	O
of	O
higher	O
age	O
group	O
patients	O
developed	O
hyperglycemia	B:C0020456
.	O

In	O
majority	O
of	O
the	O
cases	O
,	O
abnormal	B:C0205161
glucose	I:C0205161
developed	O
after	O
three	O
doses	O
of	O
L	O
-	I:C0003993
asparaginase	I:C0003993
.	O

In	O
majority	O
of	O
the	O
cases	O
,	O
abnormal	O
glucose	I:C0205161
developed	O
after	O
three	O
doses	O
of	O
L	B:C0003993
-	I:C0003993
asparaginase	I:C0003993
.	O

Hypoglycemia	B:C0020615
subsided	O
whereas	O
hyperglycemia	O
persisted	O
till	O
the	O
end	O
of	O
our	O
observation	O
period	O
.	O

Hypoglycemia	O
subsided	O
whereas	O
hyperglycemia	B:C0020456
persisted	O
till	O
the	O
end	O
of	O
our	O
observation	O
period	O
.	O

L-	B:C0003993
asparaginase	I:C0003993
produces	O
more	O
incidences	O
of	O
hypoglycemia	O
than	O
hyperglycemia	O
in	O
a	O
good	O
number	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
patients	O
towards	O
which	O
clinicians	O
should	O
be	O
more	O
vigilant	O
.	O

L-	O
asparaginase	I:C0003993
produces	O
more	O
incidences	O
of	O
hypoglycemia	B:C0020615
than	O
hyperglycemia	O
in	O
a	O
good	O
number	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
patients	O
towards	O
which	O
clinicians	O
should	O
be	O
more	O
vigilant	O
.	O

L-	O
asparaginase	I:C0003993
produces	O
more	O
incidences	O
of	O
hypoglycemia	O
than	O
hyperglycemia	B:C0020456
in	O
a	O
good	O
number	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
patients	O
towards	O
which	O
clinicians	O
should	O
be	O
more	O
vigilant	O
.	O

L-	O
asparaginase	I:C0003993
produces	O
more	O
incidences	O
of	O
hypoglycemia	O
than	O
hyperglycemia	O
in	O
a	O
good	O
number	O
of	O
acute	B:C0023449
lymphoblastic	I:C0023449
leukemia	I:C0023449
patients	O
towards	O
which	O
clinicians	O
should	O
be	O
more	O
vigilant	O
.	O

L-	O
asparaginase	I:C0003993
produces	O
more	O
incidences	O
of	O
hypoglycemia	O
than	O
hyperglycemia	O
in	O
a	O
good	O
number	O
of	O
acute	O
lymphoblastic	I:C0023449
leukemia	I:C0023449
patients	O
towards	O
which	O
clinicians	B:C0871685
should	O
be	O
more	O
vigilant	O
.	O

However	O
,	O
hyperglycemia	B:C0020456
persists	O
for	O
a	O
longer	O
duration	O
than	O
hypoglycemia	O
.	O

However	O
,	O
hyperglycemia	O
persists	O
for	O
a	O
longer	O
duration	O
than	O
hypoglycemia	B:C0020615
.	O

